U.S. markets close in 6 hours 14 minutes

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
0.9927+0.0372 (+3.89%)
A partir del 09:46AM EDT. Mercado abierto.

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionano.com

Sector(es)Healthcare
IndustriaMedical Instruments & Supplies
Empleados a tiempo completo344

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Robert Erik Holmlin M.B.A., Ph.D.President, CEO & Director612.62kN/D1968
Mr. Mark OldakowskiChief Operating Officer472.91kN/D1974
Dr. Alka Chaubey FACMG, Ph.D.Chief Medical Officer452.91kN/D1973
Ms. Gulsen Kama M.B.A.Chief Financial OfficerN/DN/D1973
Mr. Mark Adamchak CPAVP of Accounting & ControllerN/DN/DN/D
Mr. Jonathan Dixon J.D.General Counsel & SecretaryN/DN/D1975
Mr. Stanislas Marin M.B.A., M.S.Vice President of Global SalesN/DN/DN/D
Ms. Donna PolizioGlobal Head of Market AccessN/DN/DN/D
Mr. Cory KreeckGlobal Head of People OperationsN/DN/DN/D
Dr. Klint Rose Ph.D.Head of Research & DevelopmentN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Bionano Genomics, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 8; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.